| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular target of Sagittatoside B is not fully characterized. It exerts anti-inflammatory and cytoprotective effects by modulating inflammation-related signaling pathways. The compound shows antioxidant activity, likely through scavenging reactive oxygen species (ROS) and upregulating endogenous antioxidant defense systems. As a flavonoid glycoside, it may interact with various cellular targets including kinases, transcription factors, and enzymes involved in inflammatory and oxidative stress responses.
|
|---|---|
| ln Vitro |
Sagittatoside B is a flavonoid glycoside with antioxidant and anti-inflammatory properties. It is isolated from traditional Chinese herb Yinyanghuo (Herba Epimedii). The compound demonstrates potent antioxidant activity, likely through its ability to scavenge free radicals and modulate redox signaling. It also exhibits anti-inflammatory effects by modulating inflammation-related signaling pathways, which may involve inhibition of NF-κB and MAPK pathways. The compound shows cytoprotective effects, protecting cells from oxidative damage.
|
| ln Vivo |
No specific in vivo activity data are documented for Sagittatoside B. As a natural product with anti-inflammatory and antioxidant properties, it has potential for in vivo efficacy in models of inflammation, oxidative stress, and skin disorders. The compound's natural origin and traditional use suggest it may be well-tolerated. Further in vivo studies including pharmacokinetics and efficacy in animal models of inflammation or oxidative damage would be valuable for therapeutic development.
|
| Enzyme Assay |
In vitro antioxidant assays are commonly used to evaluate Sagittatoside B. The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay involves incubating varying concentrations of the compound with DPPH solution (0.1 mM in ethanol) for 30 minutes at room temperature. The decrease in absorbance at 517 nm is measured. ABTS radical scavenging, FRAP (ferric reducing antioxidant power), and ORAC (oxygen radical absorbance capacity) assays can also be performed. For anti-inflammatory activity, enzyme assays measuring COX-2 or LOX inhibition may be conducted. The compound's antioxidant activity contributes to its cytoprotective effects.
|
| Cell Assay |
Cell-based assays for Sagittatoside B include evaluation of anti-inflammatory and cytoprotective effects. Macrophage cell lines (e.g., RAW 264.7) are treated with varying concentrations of Sagittatoside B (1-100 μM) for 1-2 hours prior to stimulation with LPS (1 μg/mL) for 24 hours. Inflammatory markers such as NO (Griess assay), TNF-α, IL-6, and IL-1β (ELISA) are measured. For cytoprotection, cells are pre-treated with the compound and then exposed to oxidative stress (e.g., H₂O₂). Cell viability is measured by MTT or CCK-8 assays. The compound shows concentration-dependent anti-inflammatory and cytoprotective effects.
|
| Animal Protocol |
No specific in vivo animal models are documented for Sagittatoside B. For potential in vivo studies, the compound could be administered orally or intraperitoneally to rodents in models of inflammation (e.g., carrageenan-induced paw edema, LPS-induced systemic inflammation) or oxidative stress. Doses would be selected based on preliminary pharmacokinetic and tolerability assessments. Endpoints may include inflammatory cytokine levels, tissue histology, oxidative stress markers (MDA, SOD, GSH), and behavioral observations. The compound's natural origin suggests it may be suitable for oral administration.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are available for Sagittatoside B. As a flavonoid glycoside with a molecular weight of 646.64, the compound is relatively large and hydrophilic, which may limit oral bioavailability. Flavonoid glycosides are typically metabolized by gut microbiota to release the aglycone, which may be absorbed. The compound should be stored as powder under appropriate conditions. Solubility in aqueous and organic solvents should be determined experimentally. Further PK studies would be necessary for in vivo applications.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Sagittatoside B. As a natural compound isolated from a traditional Chinese herb, it is expected to have low toxicity based on traditional use. However, systematic toxicity studies including acute toxicity, subchronic toxicity, genotoxicity, and organ-specific toxicity would be required for therapeutic development. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Sagittatoside B is a glycoside belonging to the flavonoid class of compounds. It has been reported to exist in Epimedium saurischia, Epimedium bifolium, and other organisms with relevant data.
Sagittatoside B has the IUPAC name 3-[(6-deoxy-2-O-β-D-xylopyranosyl-α-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one. It has a purity of ≥98%. The compound is a flavonoid glycoside with a sugar moiety consisting of a deoxy-mannose (rhamnose) with a xylose substitution. It is isolated from Herba Epimedii, a plant used in traditional Chinese medicine for various conditions including osteoporosis and erectile dysfunction. The compound is for research use only. |
| Molecular Formula |
C32H38O14
|
|---|---|
| Molecular Weight |
646.6357
|
| Exact Mass |
646.226
|
| CAS # |
118525-36-3
|
| PubChem CID |
10146160
|
| Appearance |
White to yellow solid powder
|
| Density |
1.53
|
| Boiling Point |
895.5±65.0 °C at 760 mmHg
|
| Flash Point |
286.5±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.674
|
| LogP |
5.03
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
46
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O[C@H]5[C@@H]([C@H]([C@@H](CO5)O)O)O)O)O
|
| InChi Key |
BVDGQVAUJNUPGW-JGSSSOFVSA-N
|
| InChi Code |
InChI=1S/C32H38O14/c1-13(2)5-10-17-18(33)11-19(34)21-24(38)29(27(44-28(17)21)15-6-8-16(41-4)9-7-15)45-32-30(25(39)22(36)14(3)43-32)46-31-26(40)23(37)20(35)12-42-31/h5-9,11,14,20,22-23,25-26,30-37,39-40H,10,12H2,1-4H3/t14-,20+,22-,23-,25+,26+,30+,31-,32-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4R,5R,6S)-4,5-dihydroxy-6-methyl-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~154.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5465 mL | 7.7323 mL | 15.4646 mL | |
| 5 mM | 0.3093 mL | 1.5465 mL | 3.0929 mL | |
| 10 mM | 0.1546 mL | 0.7732 mL | 1.5465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
